SCHEMBL16618671

SCHEMBL16618671

Cc1ccc(Nc2ccc3c(C(=O)N(C)C)cn(S(=O)(=O)c4cccnc4)c3c2)c(F)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC2 Q92769 1/20 0.39
TNFSF11 O14788 1/20 0.37
TNF P01375 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
GFER P55789 1/20 0.34
NAMPT P43490 2/20 0.34
POLB P06746 2/20 0.34
FBP1 P09467 1/20 0.34
HTT P42858 2/20 0.33
MAPT P10636 1/20 0.33
RECQL P46063 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
BRAF P15056 1/20 0.33
PLK1 P53350 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619031 0.89 HDAC1 (0.42) HDAC1HDAC6HDAC2TNFSF11TNF
SCHEMBL17971588 0.85 LMNA (0.42) HDAC1HDAC6HDAC2GAANAMPT
SCHEMBL16618817 0.85 HDAC1 (0.41) HDAC1HDAC6HDAC2TNFSF11TNF
SCHEMBL16618614 0.85 FBP1 (0.42) HDAC1HDAC6HDAC2TNFSF11NAMPT
SCHEMBL16619336 0.85 HDAC1 (0.42) HDAC1HDAC6HDAC2TNFSF11TNF
SCHEMBL16618694 0.84 LMNA (0.40) HDAC1HDAC6HDAC2SMN1; SMN2NAMPT
SCHEMBL16619222 0.84 HDAC1 (0.42) HDAC1HDAC6HDAC2TNFSF11TNF
SCHEMBL16618617 0.83 HDAC1 (0.39) HDAC1HDAC6HDAC2TSHRNAMPT
SCHEMBL17971589 0.82 HDAC1 (0.42) HDAC1HDAC6HDAC2SMN1; SMN2GAA
SCHEMBL16626437 0.82 IDE (0.36) SMN1; SMN2GAATSHRGFERNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US claimed
EP-3052484-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME Daewoong Pharmaceutical Co., Ltd. (KR) 2016-08-10 EP claimed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US claimed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
EP-3052484-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME Daewoong Pharmaceutical Co., Ltd. (KR) 2016-08-10 EP disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HDAC1 2895/4885HDAC6 3570/4885HDAC2 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.